{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:44:25Z","timestamp":1778658265704,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008783","name":"National Research Council of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.yrtph.2020.104733","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T11:06:39Z","timestamp":1596452799000},"page":"104733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Four-week repeated dose oral toxicity study of KDS2010, a novel selective monoamine oxidase B inhibitor, in Sprague Dawley rats"],"prefix":"10.1016","volume":"117","author":[{"given":"Kyung-Tai","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Seok","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Young","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hyuk","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doo-Wan","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Ko","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Duk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Su","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Cheol","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2020.104733_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40263-017-0408-1","article-title":"Safinamide: a review in Parkinson's disease","volume":"31","author":"Blair","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yrtph.2020.104733_bib2","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1212\/WNL.67.7_suppl_2.S18","article-title":"Safinamide: from molecular targets to a new anti-Parkinson drug","volume":"67","author":"Caccia","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.yrtph.2020.104733_bib3","first-page":"622","article-title":"Xadago (Safinamide): a Monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson's disease","volume":"42","author":"Cruz","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2020.104733_bib4","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/mds.21048","article-title":"Effects of tyramine administration in Parkinson's disease patients treated with selective MAO\u2010B inhibitor rasagiline","volume":"21","author":"deMarcaida","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.yrtph.2020.104733_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/1871527316666170124165222","article-title":"Monoamine oxidase B inhibitors in Parkinson's disease","volume":"16","author":"D\u00e9zsi","year":"2017","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.yrtph.2020.104733_bib6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fphar.2016.00340","article-title":"Inhibitors of MAO-A and MAO-B in psychiatry and neurology","volume":"7","author":"Finberg","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yrtph.2020.104733_bib7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5414\/CPP48633","article-title":"Medical treatment of Parkinson's disease: today and the future","volume":"48","author":"Gardian","year":"2010","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.yrtph.2020.104733_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3233\/JPD-160847","article-title":"Efficacy of rotigotine at different stages of Parkinson's disease symptom severity and disability: a post hoc analysis according to baseline Hoehn and Yahr stage","volume":"6","author":"Giladi","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.yrtph.2020.104733_bib9","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/01.wnl.0000210692.95595.1c","article-title":"Safety of rasagiline in elderly patients with Parkinson disease","volume":"66","author":"Goetz","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.yrtph.2020.104733_bib10","series-title":"Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation","author":"Greaves","year":"2011"},{"key":"10.1016\/j.yrtph.2020.104733_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5625\/lar.2010.26.2.153","article-title":"Reference data of the main physiological parameters in control Sprague-Dawley rats from pre-clinical toxicity studies","volume":"26","author":"Han","year":"2010","journal-title":"Lab. Anim. Res."},{"key":"10.1016\/j.yrtph.2020.104733_bib12","series-title":"Toxicologic Pathology","first-page":"224","article-title":"Spontaneous lesions in control animals used in toxicity studies","author":"Johnson","year":"2013"},{"key":"10.1016\/j.yrtph.2020.104733_bib13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.yrtph.2020.104733_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s004150050104","article-title":"A study of visual hallucinations in patients with Parkinson's disease","volume":"244","author":"Klein","year":"1997","journal-title":"J. Neurol."},{"key":"10.1016\/j.yrtph.2020.104733_bib15","first-page":"268","article-title":"Historical control data from 4-week repeated toxicity studies in Crj: CD (SD) rats","volume":"18","author":"Lee","year":"2012","journal-title":"J. Exp. Med. Sci."},{"key":"10.1016\/j.yrtph.2020.104733_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/nmt.13.77","article-title":"NMDA antagonists as Parkinson's disease therapy: disseminating the evidence","volume":"4","author":"Majl\u00e1th","year":"2014","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.yrtph.2020.104733_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","article-title":"Understanding dopaminergic cell death pathways in Parkinson disease","volume":"90","author":"Michel","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.yrtph.2020.104733_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1090-0233(02)00250-2","article-title":"Sensitivity of different prothrombin time assays to factor VII deficiency in canine plasma","volume":"166","author":"Mischke","year":"2003","journal-title":"Vet. J."},{"key":"10.1016\/j.yrtph.2020.104733_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00002826-200009000-00006","article-title":"Adverse drug reactions to selegiline: a review of the French pharmacovigilance database","volume":"23","author":"Montastruc","year":"2000","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.yrtph.2020.104733_bib20","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1111\/bph.14437","article-title":"Selegiline reduces adiposity induced by high\u2010fat, high\u2010sucrose diet in male rats","volume":"175","author":"Nagy","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl. 1 Pt","key":"10.1016\/j.yrtph.2020.104733_bib21","doi-asserted-by":"crossref","first-page":"430A","DOI":"10.1097\/00002826-199201001-00225","article-title":"Reversible monoamine oxidase-A inhibitors in resistant major depression","volume":"15","author":"Nolen","year":"1992","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.yrtph.2020.104733_bib22","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1517\/13543784.17.7.1115","article-title":"An expert opinion on safinamide in Parkinson's disease","volume":"17","author":"Onofrj","year":"2008","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.yrtph.2020.104733_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.etp.2005.10.002","article-title":"Clinical chemistry and haematology historical data in control Sprague-Dawley rats from pre-clinical toxicity studies","volume":"57","author":"Petterino","year":"2006","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2020.104733_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/jm970599m","article-title":"Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives","volume":"41","author":"Pevarello","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yrtph.2020.104733_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","article-title":"MAO-inhibitors in Parkinson's disease","volume":"20","author":"Riederer","year":"2011","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.yrtph.2020.104733_bib26","unstructured":"Standard, T., Agent, A., PRODUCT MONOGRAPH TEVA-SELEGILINE."},{"key":"10.1016\/j.yrtph.2020.104733_bib27","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/WNL.67.7_suppl_2.S24","article-title":"Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition","volume":"67","author":"Stocchi","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.yrtph.2020.104733_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1517\/17425255.2011.557066","article-title":"Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists","volume":"7","author":"Szab\u00f3","year":"2011","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.yrtph.2020.104733_bib29","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/med.21561","article-title":"Monoamine oxidase\u2010B inhibitors as potential neurotherapeutic agents: an overview and update","volume":"39","author":"Tripathi","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.yrtph.2020.104733_bib30","series-title":"Fundamentals of Toxicologic Pathology","author":"Wallig","year":"2017"},{"key":"10.1016\/j.yrtph.2020.104733_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bmc.2017.11.036","article-title":"Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy","volume":"26","author":"Yeon","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.yrtph.2020.104733_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-011-0697-3","article-title":"Kynurenines in Parkinson's disease: therapeutic perspectives","volume":"119","author":"Z\u00e1dori","year":"2012","journal-title":"J. Neural. Transm."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230020301598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230020301598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:31:08Z","timestamp":1759494668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230020301598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":32,"alternative-id":["S0273230020301598"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2020.104733","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Four-week repeated dose oral toxicity study of KDS2010, a novel selective monoamine oxidase B inhibitor, in Sprague Dawley rats","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2020.104733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104733"}}